European Medical Solutions 2020 AR2
The report outlines ASIT biotech's activities and financial performance for the fiscal year 2020, a period marked by judicial reorganization and the search for a business partner. Following the failure of its lead product gp-ASIT+ to meet its primary endpoint in late 2019, the company minimized operating expenses, laid off almost all employees, and signed a binding agreement with DMS Group to contribute its imaging business. Financially, the company reported an operating loss of 0.90 million euros, down from 15.95 million euros in 2019, as all research and development activities in the allergy field were halted.
Company: European Medical Solutions
Sector: Manufacturing
Country: Belgium
Year: 2020
Type: AR2
Pages: 90
Back to company
European Medical Solutions
Annual Report
The report outlines ASIT biotech's activities and financial performance for the fiscal year 2020, a period marked by judicial reorganization and the search for a business partner. Following the failure of its lead product gp-ASIT+ to meet its primary endpoint in late 2019, the company minimized operating expenses, laid off almost all employees, and signed a binding agreement with DMS Group to contribute its imaging business. Financially, the company reported an operating loss of 0.90 million euros, down from 15.95 million euros in 2019, as all research and development activities in the allergy field were halted.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Jan 1, 2020 - Dec 31, 2020
Fiscal Year
2020
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees